New drug targets Hard-to-Treat prostate cancer
Disease control
Recruiting now
This phase 2 trial tests a drug called FG-3246, which is designed to seek out and attack prostate cancer cells that have a specific marker (CD46) on their surface. The study will enroll 75 men with metastatic castration-resistant prostate cancer that has worsened after hormone th…
Phase: PHASE2 • Sponsor: Kyntra Bio • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC